Table 2.
Medication treatment record of the 47 bipolar manic subjectsa
| Treatment (Week 0 ∼ Week 8) | Week 0 dose | Ending dose | Min. dose | Max. dose | Treatment prior to Week 0 |
|---|---|---|---|---|---|
| Lithium + olanzapine | LITH 500-750 mg/d + OLAN 5-10 mg/d × 4d (n = 2); LITH 750 mg/d × 4d (n = 1) | ||||
| Subjects, n | 20 | ||||
| Lithium carbonate, mean (SD) | 525 (112) | 981 (190) | 250 | 1250 | |
| Olanzapine, mean (SD) | 7.63 (3.86) | 7.00 (3.50) | 5 | 15 | |
| With ECT, n | 10 | ||||
| Without ECT, n | 10 | ||||
| Lithium + quetiapine | |||||
| Subjects, n | 2 | ||||
| Lithium carbonate, mean (SD) | 500 (0) | 1125 (177) | 500 | 1250 | |
| Quetiapine, mean (SD) | 50 (0) | 300 (141) | 50 | 400 | |
| With ECT, n | 1 | ||||
| Without ECT, n | 1 | ||||
| Lithium + risperidone | |||||
| Subjects, n | 2 | ||||
| Lithium carbonate, mean (SD) | 500 (0) | 500 (0) | 500 | 500 | |
| Risperidone, mean (SD) | 1(0) | 3 (0) | 1 | 3 | |
| With ECT, n | 2 | ||||
| Without ECT, n | 0 | ||||
| Lithium | |||||
| Subjects, n | 2 | ||||
| Lithium, mean (SD) | 550 (112) | 1050 (209) | 500 | 1250 | |
| With ECT, n | 1 | ||||
| Without ECT, n | 1 | ||||
| Valproate + olanzapine | VAL 500 mg/d + QUET 300 mg/d × 4d (n = 1) | ||||
| Subjects, n | 5 | ||||
| Valproate, mean (SD) | 600 (224) | 1000 (0) | 500 | 1000 | |
| Olanzapine, mean (SD) | 8.00 (2.74) | 7.50 (3.54) | 5 | 10 | |
| With ECT, n | 1 | ||||
| Without ECT, n | 4 | ||||
| Valproate | VAL 500-1000 mg/d × 2d (n = 2) | ||||
| Subjects, n | 3 | ||||
| Valproate, mean (SD) | 700 (265) | 1067 (275) | 500 | 1250 | |
| With ECT, n | 0 | ||||
| Without ECT, n | 3 | ||||
| Lithium + valproate + olanzapine | |||||
| Subjects, n | 3 | ||||
| Lithium, mean (SD) | 750 (250) | 1000 (0) | 500 | 1000 | |
| Valproate, mean (SD) | 500 (0) | 1000 (0) | 500 | 1000 | |
| Olanzapine, mean (SD) | 6.67 (2.89) | 5.00 (0) | 5 | 5 | |
| With ECT, n | 0 | ||||
| Without ECT, n | 3 | ||||
| Lithium + valproate + quetiapine | LITH 500 mg/d × 1d (n = 1) | ||||
| Subjects, n | 5 | ||||
| Lithium, mean (SD) | 460 (89) | 930 (208) | 300 | 1250 | |
| Valproate, mean (SD) | 620 (217) | 838 (197) | 500 | 1000 | |
| Quetiapine, mean (SD) | 150 (71) | 283 (275) | 100 | 600 | |
| With ECT, n | 3 | ||||
| Without ECT, n | 2 | ||||
| Lithium + valproate + risperidone | |||||
| Subjects, n | 1 | ||||
| Lithium, mean (SD) | 500 (0) | 500 (0) | 500 | 500 | |
| Valproate, mean (SD) | 500 (0) | 250 (0) | 500 | 250 | |
| Risperidone, mean (SD) | 2 (0) | 0 (0) | 2 | 0 | |
| With ECT, n | 1 | ||||
| Without ECT, n | 0 | ||||
| Lithium + valproate | LITH 500 mg/d × 1d (n = 1) | ||||
| Subjects, n | 2 | ||||
| Lithium, mean (SD) | 250 (354) | 1000 (0) | 500 | 1000 | |
| Valproate, mean (SD) | 500 (0) | 1250 (0) | 500 | 1250 | |
| With ECT, n | 0 | ||||
| Without ECT, n | 2 | ||||
| Olanzapine | OLAN 10∼15mg/d × 2d (n = 1) | ||||
| Subjects, n | 2 | ||||
| Olanzapine, mean (SD) | 11.25 (5.30) | 15.00 (0) | 7.5 | 15 | |
| With ECT, n | 1 | ||||
| Without ECT, n | 1 | ||||
| Total, n | Week 0 | Week 8 | n = 9 | ||
| Subjects | 47 | 28 | |||
| With ECT | 20 | 13 | |||
| Without ECT | 27 | 15 |
ECT = electroconvulsive therapy; LITH = lithium; OLAN = olanzapine; VAL = valproate; QUET = quetiapine.
a
Drug doses reported as mg/day.